Thalassemia
Thalassemia is an inherited blood disorder that affects the production of hemoglobin, a protein found in red blood cells that
carries oxygen throughout the body.
People with thalassemia have an abnormal hemoglobin production, leading to a shortage of healthy red blood cells. Treatment options for thalassemia include blood transfusions, iron chelation therapy, and bone marrow transplantation (BMT), also known as hematopoietic stem cell transplantation (HSCT).
BMT involves replacing a patient's diseased bone marrow with healthy bone marrow stem cells from a donor. The new stem cells will produce healthy red blood cells, which can help to reduce the patient's symptoms.
In thalassemia, BMT is used to replace the patient's abnormal hemoglobin-producing cells with healthy ones. BMT is often used when other treatments have failed or when the patient's condition is severe.
BMT can be a potential cure for thalassemia, but it is a complex and potentially risky procedure. One of the biggest challenges of BMT is finding a suitable donor for the patient. A donor must have a similar tissue type as the patient to prevent rejection of the transplant.
Patients who do not have a matched donor can sometimes receive a transplant from a family member who is a partial match or from an unrelated donor through a registry of bone marrow donors.
In summary, BMT is a treatment option for patients with thalassemia, where it can replace the patient's abnormal hemoglobin-producing cells with healthy ones. BMT is a complex and potentially risky procedure that requires careful matching of donors and recipients.
However, for some patients with thalassemia, BMT can be a potential cure and can help to improve their symptoms and overall quality of life.
Do you want to be our solution partner?
